EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade

Nicola Principe iD, Amber-Lee Phung, Kofi L P Stevens, Omar Elaskalani, Ben Wylie, Caitlin M Tilsed, Fezaan Sheikh, M Lizeth Orozco Morales, Joel Kidman, Elly Marcq, Scott A Fisher, Anna K Nowak und 3 weitere

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2023-008568 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Nicola Principe und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Respiratory Health, National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Western Australia, Austr…. Hauptthemen laut MEDLINE: Lymphocyte Activation Gene 3 Protein, Lymphocytes, Tumor-Infiltrating, Immune Checkpoint Inhibitors, Antigens, CD. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: New South Wales Workers' Compensation Dust Disease Board, WA Department of Health, Simon Lee Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein/ligand 1 (PD-1/PD-L1) are approved for treatment of multiple cancer types. Chemotherapy is often administered with immune checkpoint blockade (ICB) therapies that target CTLA-4 and/or PD-(L)1. ICB targeting other immune checkpoints such as lymphocyte activating gene-3 (LAG-3) has the potential to improve antitumor responses when combined with chemotherapy. Response to anti-PD-1 ICB is dependent on progenitor exhausted CD8 + T cells (T PEX ) in the tumor, but it is unclear how chemotherapy alters T PEX proportions and phenotype.

Methods

Here we investigated whether sequential chemotherapy altered T PEX frequency and immune checkpoint expression in multiple murine tumor models.

Results

Two doses of two different anti-metabolite chemotherapies increased tumor infiltrating CD4 + , and CD8 + T PEX expressing LAG-3 in multiple mouse models, which was not restricted to tumor antigen specific CD8 + T cells. To determine if LAG-3 + tumor infiltrating lymphocytes (TILs) could be targeted to improve tumor control, we administered anti-LAG-3 and anti-PD-1 ICB after two doses of chemotherapy and found combination therapy generated robust antitumor responses compared with each agent alone. Both anti-LAG-3 and anti-PD-1 ICB with chemotherapy were required for the complete tumor regression observed.

Conclusions

Changes in immune checkpoint expression on TILs during chemotherapy administration informs selection of ICB therapies to combine with.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphocyte Activation Gene 3 ProteinLymphocytes, Tumor-InfiltratingImmune Checkpoint InhibitorsAntigens, CDAnimalsMiceFemaleHumansCD8-Positive T-LymphocytesAntineoplastic Combined Chemotherapy ProtocolsCell Line, Tumor

Stichwörter der Autor:innen

ChemotherapyCombination therapyImmune checkpoint inhibitorsT-lymphocytes

Substanzen

Lymphocyte Activation Gene 3 ProteinImmune Checkpoint InhibitorsAntigens, CDLag3 protein, mouseLag3 protein, human

Autor:innen und Institutionen

  • Institute for Respiratory Health, National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Western Australia, Australia.
  • School of Biomedical Sciences, The University of Western Australia, Perth, Western Australia, Australia.
  • Telethon Kids Institute, Nedlands, Western Australia, Australia.
  • Perelman School of Medicine, Pulmonary, Allergy and Critical Care Division, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerpen, Belgium.
  • Brussels Center for Immunology, Vrije Universiteit Brussel, Brussels, Belgium.

ORCID-Profile: Nicola Principe, Jonathan Chee

Förderung

  • New South Wales Workers' Compensation Dust Disease Board
  • WA Department of Health
  • Simon Lee Foundation
  • Raine Foundation
  • Cancer Council Western Australia
  • National Health and Medical Research Council
  • Faculty of Medicine, Dentistry and Health Sciences, University of Western Australia

Zitieren

APA

Principe, N., Phung, A. L., Stevens, K. L. P., Elaskalani, O., Wylie, B., Tilsed, C. M., Sheikh, F., Orozco Morales, M. L., Kidman, J., Marcq, E., Fisher, S. A., Nowak, A. K., McDonnell, A. M., Lesterhuis, W. J., & Chee, J. (2024). Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-008568

Vancouver

Principe N, Phung AL, Stevens KLP, Elaskalani O, Wylie B, Tilsed CM, et al. Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-008568

BibTeX
@article{Principe2024,
  author = {Principe, Nicola and Phung, Amber-Lee and Stevens, Kofi L P and Elaskalani, Omar and Wylie, Ben and Tilsed, Caitlin M and Sheikh, Fezaan and Orozco Morales, M Lizeth and Kidman, Joel and Marcq, Elly and Fisher, Scott A and Nowak, Anna K and McDonnell, Alison M and Lesterhuis, W Joost and Chee, Jonathan},
  title = {Anti-metabolite chemotherapy increases LAG-3 expressing tumor-infiltrating lymphocytes which can be targeted by combination immune checkpoint blockade},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2023-008568}
}
Kostenlos starten →